HRMY

Harmony Biosciences Holdings, Inc. (HRMY) | Rumor.io

Harmony Biosciences Holdings

HRMY

Attention (50-day avg)0%

Attention rank (50-day avg)#2,650

Bullish sentiment (50-day avg)100%

Price to earnings ratio12.9

Market capitalization2.3B

Earnings per share3.09

Dividend yield (TTM)—

Revenue (annual)868.5M

Net income (annual)158.7M

Social

What share of all stock conversation is about HRMY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Feb 25

Harmony Biosciences Holdings, Inc. (HRMY) is on track to reach $1B in sales this year, according to recent developments.
The company has been growing consistently, with a solid profit margin and a cash reserve of over $700M, making it a profitable and financially stable biotech name.
HRMY is expected to present Phase 3 Dravet Syndrome results in 1H27 for Clemizole, and Phase 3 Narcolepsy results in YE27 for Pitolisant, with Phase 1 Narcolepsy results already presented in 3Q26.

Generated by AI

Sentiment

Of the messages about HRMY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	94.4% +14.75
Bearish	—	—	0% 0	5.6% -14.75

Bullish· Aug 14

Harmony Biosciences Holdings, Inc. (HRMY) is acquiring Zynerba Pharmaceuticals, Inc. (ZYNE) for up to $200M, with $60M in cash and $140M in a CVR.
HRMY has a strong cash position, with $44M in cash and $0.3M in debt, making the acquisition a potentially good deal for both parties.
The acquisition is expected to drive significant growth, with one investor predicting HRMY will reach $5.00 and another targeting a price of $1.66, citing the stock's massive momentum and potential for further price appreciation.

Bearish· Mar 28

$HRMY is down 26% after a short-seller's report suggested problems with its narcolepsy drug, Wakix.
A Mizuho analyst disputes the report's findings, calling the language and evidence "potentially misleading and inflated."
Institutions are likely to dump $HRMY shares due to the allegations, as no one wants to own a company with a reputation for scandal.

Generated by AI

Topics

Of the messages about HRMY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	69.45%
Technical Analysis	—	—	0%	4.18%
Analysts	—	—	0%	22.86%
Earnings	—	—	0%	2.64%
Controversies	—	—	0%	0.44%
Macro	—	—	0%	0.44%

Announcements· Aug 14

Harmony Biosciences Holdings, Inc. ($HRMY) is acquiring Zynerba Pharmaceuticals, Inc. ($ZYNE) for $60 million in cash, plus a CVR representing the right to receive up to $140 million in additional payments.
The CVR is payable upon achievement of certain milestones, including the completion of trials and the attainment of sales milestones, and could be worth up to $2.5444 per share.
The acquisition will be funded by Harmony Biosciences' existing cash on hand, which totals $429.6 million, leaving the company with a significant cash reserve.

Controversies· Mar 29

Harmony Biosciences Holdings, Inc. is facing allegations that it is not strongly denying them and not counter-suing Scorpion.
The company is being investigated by several law firms on behalf of investors regarding potential securities law violations.
Harmony's protestations of innocence may lack credibility unless they file a lawsuit against the parties making false accusations.

Generated by AI

Community

Of the messages about HRMY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	7.14%	28.55%
Newcomers	0%	0%	92.86%	71.45%

Regulars· May 2

Regulars are questioning the authenticity of Harmony Biosciences' Q4 revenue and earnings, suggesting possible accounting irregularities.
The company's Q1 2023 earnings beat expectations, with non-GAAP EPS of $0.66 and revenue of $119.13M, but the impact of deferred losses and taxes on revenue is unclear.
Harmony Biosciences reported its Q1 2023 financial results and business updates, filing an 8-K and 10-Q with the SEC, and also filed an S-8 registration statement for employee stock options.

Newcomers· Jan 30

Newcomers to the market are looking at Harmony Biosciences Holdings, Inc. ($HRMY) for potential growth opportunities due to its innovative approach to healthcare solutions.
Investors are concerned about the potential for $HRMY to capitalize on the increasing demand for digital health services and biosimilar products.
The company's focus on rare disease treatments and its commitment to improving patient outcomes are seen as key factors in its long-term success.

Generated by AI

News

Oppenheimer reiterates Harmony Biosciences stock rating on patent defense

6d agoInvesting.com

Harmony Biosciences CMO sells $1.65m in shares

11d agoInvesting.com

Engaging In Options Activity, Kumar Budur Exercises Options Valued At $262K In Harmony Biosciences Hldgs

19d agobenzinga.com

Harmony Biosciences at cantor conference: growth plan widens

20d agoInvesting.com

Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?

26d agofinance.yahoo.com

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company’s investigation of EPX-100 (clemizole hydrochloride) at the 16th European Epilepsy Congress being held from September 5-9, in Athens, Greece. The company is investigating EPX-100 for the treatment of Dravet syndrome and Lennox-Gastaut syndrome in the ongoing ARGUS and LIGHTHOUSE trials, respectively. These trials are current

26d agofinance.yahoo.com

Also Discussed

Investors talking about HRMY also mention

#	Name	Attention
1	ZYNE - Zynerba Pharmaceuticals, Inc.	——
2	Lantheus Holdings Inc.LNTH	0%0
3	Zymeworks Inc.ZYME	0%0
4	CNTA - Centessa Pharmaceuticals plc	——
5	Relay Therapeutics Inc.RLAY	0%new
6	Allient Inc.ALNT	0%0
7	AGFS - AgroFresh Solutions, Inc.	——
8	AVDL - Avadel Pharmaceuticals plc	——
9	Takeda Pharmaceutical Company Limited American Depositary ReceiptTAK	0%0
10	Corbus Pharmaceuticals Holdings, Inc.CRBP	0%0

Harmony Biosciences Holdings, Inc.

Healthcare
Biotechnology

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases and other unmet medical needs. The company’s portfolio centers on treatments for sleep-wake disorders and related neurological conditions, with a strong emphasis on patients whose options remain limited. Its marketed therapy, WAKIX, is designed for the treatment of excessive daytime sleepiness in adults with narcolepsy, reflecting the company’s focus on specialized neuroscience care. Harmony Biosciences also advances research programs in adjacent rare neurological and endocrine disorders, combining commercial operations with clinical development capabilities. Headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences plays a focused role in the biopharmaceutical market by addressing niche patient populations through targeted, science-driven therapies.

Website

Location

630 West Germantown Pike

Plymouth Meeting, PA, 19462

United States

Social

What share of all stock conversation is about HRMY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Feb 25

Harmony Biosciences Holdings, Inc. (HRMY) is on track to reach $1B in sales this year, according to recent developments.
The company has been growing consistently, with a solid profit margin and a cash reserve of over $700M, making it a profitable and financially stable biotech name.
HRMY is expected to present Phase 3 Dravet Syndrome results in 1H27 for Clemizole, and Phase 3 Narcolepsy results in YE27 for Pitolisant, with Phase 1 Narcolepsy results already presented in 3Q26.

Generated by AI

Sentiment

Of the messages about HRMY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	94.4% +14.75
Bearish	—	—	0% 0	5.6% -14.75

Bullish· Aug 14

Harmony Biosciences Holdings, Inc. (HRMY) is acquiring Zynerba Pharmaceuticals, Inc. (ZYNE) for up to $200M, with $60M in cash and $140M in a CVR.
HRMY has a strong cash position, with $44M in cash and $0.3M in debt, making the acquisition a potentially good deal for both parties.
The acquisition is expected to drive significant growth, with one investor predicting HRMY will reach $5.00 and another targeting a price of $1.66, citing the stock's massive momentum and potential for further price appreciation.

Bearish· Mar 28

$HRMY is down 26% after a short-seller's report suggested problems with its narcolepsy drug, Wakix.
A Mizuho analyst disputes the report's findings, calling the language and evidence "potentially misleading and inflated."
Institutions are likely to dump $HRMY shares due to the allegations, as no one wants to own a company with a reputation for scandal.

Generated by AI

Topics

Of the messages about HRMY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	69.45%
Technical Analysis	—	—	0%	4.18%
Analysts	—	—	0%	22.86%
Earnings	—	—	0%	2.64%
Controversies	—	—	0%	0.44%
Macro	—	—	0%	0.44%

Announcements· Aug 14

Harmony Biosciences Holdings, Inc. ($HRMY) is acquiring Zynerba Pharmaceuticals, Inc. ($ZYNE) for $60 million in cash, plus a CVR representing the right to receive up to $140 million in additional payments.
The CVR is payable upon achievement of certain milestones, including the completion of trials and the attainment of sales milestones, and could be worth up to $2.5444 per share.
The acquisition will be funded by Harmony Biosciences' existing cash on hand, which totals $429.6 million, leaving the company with a significant cash reserve.

Controversies· Mar 29

Harmony Biosciences Holdings, Inc. is facing allegations that it is not strongly denying them and not counter-suing Scorpion.
The company is being investigated by several law firms on behalf of investors regarding potential securities law violations.
Harmony's protestations of innocence may lack credibility unless they file a lawsuit against the parties making false accusations.

Generated by AI

Community

Of the messages about HRMY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	7.14%	28.55%
Newcomers	0%	0%	92.86%	71.45%

Regulars· May 2

Regulars are questioning the authenticity of Harmony Biosciences' Q4 revenue and earnings, suggesting possible accounting irregularities.
The company's Q1 2023 earnings beat expectations, with non-GAAP EPS of $0.66 and revenue of $119.13M, but the impact of deferred losses and taxes on revenue is unclear.
Harmony Biosciences reported its Q1 2023 financial results and business updates, filing an 8-K and 10-Q with the SEC, and also filed an S-8 registration statement for employee stock options.

Newcomers· Jan 30

Newcomers to the market are looking at Harmony Biosciences Holdings, Inc. ($HRMY) for potential growth opportunities due to its innovative approach to healthcare solutions.
Investors are concerned about the potential for $HRMY to capitalize on the increasing demand for digital health services and biosimilar products.
The company's focus on rare disease treatments and its commitment to improving patient outcomes are seen as key factors in its long-term success.

Generated by AI

Harmony Biosciences Holdings

Social

Feb 25

Bullish· Aug 14

Bearish· Mar 28

Announcements· Aug 14

Controversies· Mar 29

Regulars· May 2

Newcomers· Jan 30

Oppenheimer reiterates Harmony Biosciences stock rating on patent defense

Harmony Biosciences CMO sells $1.65m in shares

Engaging In Options Activity, Kumar Budur Exercises Options Valued At $262K In Harmony Biosciences Hldgs

Harmony Biosciences at cantor conference: growth plan widens

Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

Also Discussed

Harmony Biosciences Holdings, Inc.

Company Information

Location

Oppenheimer reiterates Harmony Biosciences stock rating on patent defense

Harmony Biosciences CMO sells $1.65m in shares

Engaging In Options Activity, Kumar Budur Exercises Options Valued At $262K In Harmony Biosciences Hldgs

Harmony Biosciences at cantor conference: growth plan widens

Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

Also Discussed

Social

Feb 25

Bullish· Aug 14

Bearish· Mar 28

Announcements· Aug 14

Controversies· Mar 29

Regulars· May 2

Newcomers· Jan 30